Innovent Biologics (688428/09969) announced on July 15 details regarding the vesting outcomes of its 2023 STAR Market restricted stock incentive plan. The second vesting period for initially granted shares and the first vesting period for reserved shares will result in 2.08 million A-shares becoming tradable on July 18, 2025.
According to the disclosure, Innovent Biologics reported robust first-quarter 2025 financial performance, achieving revenue of 381 million yuan with net profit attributable to shareholders reaching 17.97 million yuan. This share release marks a significant milestone in the company's equity incentive program execution.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.